Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma

Details for Australian Patent Application No. 2001288562 (hide)

International Classifications

Event Publications

5 October 2006 Application Accepted

Published as AU-B-2001288562

25 January 2007 Assignment before Grant

Van Andel Institute; The Government of the United States of America, as represented by the Secretary of Health and Human Services The application has been assigned to The Government of the United States of America, as represented by the Secretary of Health and Human Services; Van Andel Research Institute 2002

8 February 2007 Standard Patent Sealed

25 March 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.